^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    opolimogene capmilisbac (JNJ-64041809)

    i
    Other names: JNJ-64041809 , JNJ 64041809, ADU-741, JNJ-809
    Associations

    News

    Trials
    Company:
    J&J, Novartis
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    almost3years
    Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer. (PubMed, Prostate Cancer Prostatic Dis)
    JNJ-809 has manageable safety consistent with other LADD Lm-based therapies. Limited antigen-specific immune responses were observed, which did not translate into objective clinical responses.
    Clinical • Journal
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
    |
    opolimogene capmilisbac (JNJ-64041809)
    almost6years
    Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P1; N=26; Completed; Sponsor: Janssen Research & Development, LLC; Active, not recruiting --> Completed
    Trial completion
    |
    opolimogene capmilisbac (JNJ-64041809)